이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Delta-Fly Pharma 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Kiyoshi Eshima

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	n/a
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	6.6yrs

최근 관리 업데이트

Recent updates

Is Delta-Fly Pharma (TSE:4598) In A Good Position To Deliver On Growth Plans?

May 22

CEO

Kiyoshi Eshima

no data

테뉴어

Mr. Kiyoshi Eshima serves as President & Representative Director of Delta-Fly Pharma, Inc.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Kiyoshi Eshima	President & Representative Director	no data	데이터 없음	데이터 없음
Kinichiro Kominami	Independent Outside Director	6.1yrs	데이터 없음	데이터 없음
Kenzo Iizuka	Director	11.4yrs	데이터 없음	1.03% ¥ 51.4m
Sachio Kishii	Independent Outside Director	7.1yrs	데이터 없음	데이터 없음
Masaya Kimura	Auditor	10.1yrs	데이터 없음	0.18% ¥ 9.1m
Shohei Yamamoto	External Auditor	9.4yrs	데이터 없음	데이터 없음
Kenichi Kurotaki	Director	4.1yrs	데이터 없음	데이터 없음
Akifumi Taniguchi	Independent Outside Director	3.1yrs	데이터 없음	데이터 없음
Masaaki Maeda	Full-Time Auditor	4.1yrs	데이터 없음	데이터 없음

6.6yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 이사회: 4598 의 이사회는 경험(평균 재직 기간 6.5 년)으로 간주됩니다.

Delta-Fly Pharma 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Insufficient new directors

Delta-Fly Pharma, Inc., Annual General Meeting, Jun 27, 2024

Less than half of directors are independent

Delta-Fly Pharma, Inc., Annual General Meeting, Jun 29, 2022

Less than half of directors are independent

Recent updates

Delta-Fly Pharma, Inc. Announces Enrollment of Patients in the Phase III Clinical Trial of DFP-14323

Insufficient new directors

Delta-Fly Pharma, Inc. to Report Q1, 2025 Results on Aug 09, 2024

Is Delta-Fly Pharma (TSE:4598) In A Good Position To Deliver On Growth Plans?

Delta-Fly Pharma, Inc., Annual General Meeting, Jun 27, 2024

Delta-Fly Pharma Inc. Receives Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 Combined with Venetoclax

Delta-Fly Pharma Inc. Announces FDA Submission of the Protocol of the Phase I/II Study of DFP-10917 Combined with Venetoclax (VTX) in the AML Patients Treated by VTX in the AML

Delta-Fly Pharma, Inc. to Report Fiscal Year 2024 Results on May 15, 2024

Delta-Fly Pharma Inc Announces Initiation of Phase III Pivotal Comparative Clinical Trial of DFP-14323

Delta-Fly Pharma Inc Announces Initiation of Phase III Pivotal Comparative Clinical Trial of DFP-14323

Delta-Fly Pharma, Inc. Provides Update on Interim Analysis Status of Phase III Study of DFP-10917 in Patients with R/R AML

Delta-Fly Pharma, Inc. to Report Q3, 2024 Results on Feb 13, 2024

New major risk - Shareholder dilution

New major risk - Share price stability

Delta-Fly Pharma, Inc. to Report Q2, 2024 Results on Nov 13, 2023

Delta-Fly Pharma, Inc. to Report Q1, 2024 Results on Aug 14, 2023

Third quarter 2023 earnings released: JP¥75.09 loss per share (vs JP¥51.67 loss in 3Q 2022)

Delta-Fly Pharma, Inc. announced that it has received ¥1.300842 billion in funding from Macquarie Group Limited

Delta-Fly Pharma, Inc. announced that it expects to receive ¥1.300842 billion in funding from Macquarie Group Limited

First half 2023 earnings released: JP¥115 loss per share (vs JP¥103 loss in 1H 2022)

Less than half of directors are independent

First quarter 2023 earnings released: JP¥56.83 loss per share (vs JP¥56.58 loss in 1Q 2022)

Delta-Fly Pharma, Inc. to Report Q3, 2023 Results on Feb 14, 2023

Delta-Fly Pharma, Inc., Annual General Meeting, Jun 29, 2022

Less than half of directors are independent

Delta-Fly Pharma, Inc. to Report Fiscal Year 2022 Results on May 13, 2022

New 90-day low: JP¥1,067

New 90-day low: JP¥1,119

New 90-day low: JP¥1,521

CEO

테뉴어

이사회 구성원

평균 재임 기간

평균 연령